CONNECT WITH US
HealthTech

HealthTech

Earlier valve replacement benefits some patients with moderate aortic stenosis

Medical Xpress logo

Published on

Add as a preferred source on Google
Earlier valve replacement benefits some patients with moderate aortic stenosis

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Patients with moderate aortic stenosis, a narrowing of the heart's aortic valve, may benefit from undergoing transcatheter aortic valve replacement (TAVR) before the disease becomes severe, according to findings from a clinical trial co-led by Cedars-Sinai investigators.

The study found that earlier TAVR treatment lowered the combined risk of death or a heart-failure event over two years in certain patients with moderate aortic stenosis.

Findings from the PROGRESS clinical trial were published in The New England Journal of Medicine and presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 symposium in San Diego.

Raj Makkar, M.D., vice president of cardiovascular innovation and intervention in the Smidt Heart Institute at Cedars-Sinai, is the national principal investigator for the trial.

The benefit of earlier treatment was shown by patients experiencing fewer heart-failure events, including hospitalizations, Makkar said.

"Patients with moderate aortic stenosis can already have symptoms and signs that their heart is under strain. These results show that for selected patients with at-risk features, treating the valve earlier can reduce the risk of heart-failure events before the narrowing becomes severe."

The Smidt Heart Institute at Cedars-Sinai enrolled more patients than any other participating center, giving patients a key role in advancing research into the disease.

"Our extensive experience with treating valvular heart disease, along with our ability to integrate research into routine patient care, powered our ability to enroll a significant number of patients," said Makkar, the Karsh Distinguished Chair in Interventional Cardiology.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.